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Objectives The purpose of this study was to evaluate the safety, device performance, and clinical outcome up to 2 years for
patients undergoing transcatheter aortic valve implantation (TAVI).
Background The role of TAVI in the treatment of calcific aortic stenosis evolves rapidly, but mid- and long-term results are
scarce.
Methods We conducted a prospective, multicenter, single-arm study with symptomatic patients undergoing TAVI for treat-
ment of severe aortic valve stenosis using the 18-F Medtronic CoreValve (Medtronic, Minneapolis, Minnesota)
prosthesis.
Results In all, 126 patients (mean age 82 years, 42.9% male, mean logistic European System for Cardiac Operative Risk
Evaluation score 23.4%) with severe aortic valve stenosis (mean gradient 46.8 mm Hg) underwent the TAVI pro-
cedure. Access was transfemoral in all but 2 cases with subclavian access. Retrospective risk stratification clas-
sified 54 patients as moderate surgical risk, 51 patients as high-risk operable, and 21 patients as high-risk inop-
erable. The overall technical success rate was 83.1%. Thirty-day all-cause mortality was 15.2%, without
significant differences in the subgroups. At 2 years, all-cause mortality was 38.1%, with a significant difference
between the moderate-risk group and the combined high-risk groups (27.8% vs. 45.8%, p  0.04). This differ-
ence was mainly attributable to an increased risk of noncardiac mortality among patients constituting the high-
risk groups. Hemodynamic results remained unchanged during follow-up (mean gradient: 8.5  2.5 mm Hg at
30 days and 9.0  3.4 mm Hg at 2 years). Functional class improved in 80% of patients and remained stable
over time. There was no incidence of structural valve deterioration.
Conclusions The TAVI procedure provides sustained clinical and hemodynamic benefits for as long as 2 years for patients
with symptomatic severe aortic stenosis at increased risk for surgery. (J Am Coll Cardiol 2011;57:1650–7)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.044Transcatheter aortic valve implantation (TAVI) is evolving
rapidly with an exponential growth of procedures performed
worldwide. The large unmet clinical need addressed by
TAVI relates to the suboptimal treatment options in the
past for patients with symptomatic aortic valve stenosis but
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treatment was often the only remaining option for these
patients without significant impact on symptoms and prog-
nosis (1). The enthusiasm surrounding TAVI is the result of
a simple but convincing concept, which remarkably matured
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April 19, 2011:1650–7 CoreValve 2-Year Follow-Upover the past few years. Improvements included an impor-
tant reduction in the size of device profiles, more careful
patient selection and screening processes, as well as identi-
fication of predictors of success (2). However, clinical
outcome data are mostly restricted to procedural and short-
term follow-up (3–7), whereas long-term and randomized
clinical trial data are lacking. We are reporting herein the
2-year follow-up results of the 18-F Medtronic CoreValve
(Medtronic, Minneapolis, Minnesota) prosthesis safety and
efficacy study, which is the longest follow-up reported so far
for this commercially available technology.
Methods
Study design. The study was conducted as a prospective,
ulticenter study to evaluate safety and performance of
he 18-F CoreValve prosthesis in patients undergoing
AVI for treatment of severe aortic valve stenosis. Primary
ndpoints were major adverse cardiovascular and cerebro-
ascular events (MACCE) at 30 days as well as technical
nd procedural success. Clinical and echocardiographic
valuation was performed at baseline and after the proce-
ure at 1, 6, and 12 months, and annually thereafter.
Patient inclusion criteria were defined as presence of
evere aortic stenosis (0.6 cm2/m2), aortic annulus diameter
ranging from 20 to 27 mm as determined by echocardiog-
Baseline Clinical Patient CharacteristicsTable 1 Baseline Clinical Patient Characteristics
Total
(n  126)
Moderate
(n  5
Age, yrs 81.9 6.4 83.4
Male 42.9% (54) 37.0% (2
EuroSCORE 23.43 13.80 16.14
Dyslipidemia 57.9% (73) 53.7% (2
Hypertension 79.4% (100) 75.9% (4
Diabetes mellitus 26.2% (33) 20.4% (1
Current smoker 32.5% (41) 22.2% (1
Coronary heart disease 65.9% (83) 53.7% (2
History of atrial fibrillation 39.7% (50) 37.0% (2
Previous myocardial infarction 19.0% (24) 11.1% (6
Previous CABG 26.2% (33) 9.3% (5
Previous coronary angioplasty 23.8% (30) 18.5% (1
Peripheral vascular disease 19.0% (24) 13.0% (7
Previous stroke or TIA 22.2% (28) 20.4% (1
Pulmonary hypertension 31.7% (40) 11.1% (6
Renal failure 43.7% (55) 35.2% (1
On dialysis 7.3% (4/55) 5.3% (1
Chronic lung disease 23.0% (29) 18.5% (1
Porcelain aorta 7.9% (10) 1.9% (1
Previous pacemaker 7.9% (10) 7.4% (4
History of congestive heart failure 55.6% (70) 38.9% (2
NYHA functional class I 5.6% (7) 9.3% (5
NYHA functional class II 19.8% (25) 24.1% (1
NYHA functional class III 54.0% (68) 57.4% (3
NYHA functional class IV 20.6% (26) 9.3% (5Values are mean  SD, % (n), or % (n/N).
CABG  coronary artery bypass graft surgery; EuroSCORE  European System for Cardiac Operative Rraphy, ascending aorta diameter
45 mm at the sinotubular junc-
tion, age 75 years, or surgical
risk with logistic EuroSCORE
(European System for Cardiac
Operative Risk Evaluation)15,
or 1 to 2 high-risk comorbidities
such as cirrhosis of the liver,
pulmonary insufficiency (forced
expiratory volume in 1 s 1 l),
previous cardiac surgery, pulmo-
nary hypertension (systolic pul-
monary pressure 60 mm Hg),
orcelain aorta, right ventricular
ailure, or history of mediastinal
adiation therapy.
To identify patients who would
e considered high-risk and
oderate-risk for surgical aortic
alve replacement, a retrospective
isk stratification using com-
only accepted surgical criteria
as performed by 2 independent cardiovascular surgeons
ith recognized expertise in aortic valve surgery. The sur-
eons were blinded to procedural details and outcomes but
High-Risk
Operable
(n  51)
Inoperable
(n  21)
Combined
(n  72)
82.2 7.0 77.3 6.8 80.8 7.2
43.1% (22) 57.1% (12) 47.2% (34)
29.91 14.84 26.45 13.66 28.90 14.50
56.9% (29) 71.4% (15) 61.1% (44)
82.4% (42) 81.0% (17) 81.9% (59)
29.4% (15) 33.3% (7) 30.6% (22)
39.2% (20) 42.9% (9) 40.3% (29)
74.5% (38) 76.2% (16) 75.0% (54)
37.3% (19) 52.4% (11) 41.7% (30)
21.6% (11) 33.3% (7) 25.0% (18)
41.2% (21) 33.3% (7) 38.9% (28)
23.5% (12) 38.1% (8) 27.8% (20)
21.6% (11) 28.6% (6) 23.6% (17)
23.5% (12) 23.8% (5) 23.6% (17)
41.2% (21) 61.9% (13) 47.2% (34)
51.0% (26) 47.6% (10) 50.0% (36)
7.7% (2/26) 10.0% (1/10) 8.3% (3/36)
21.6% (11) 38.1% (8) 26.4% (19)
3.9% (2) 33.3% (7) 12.5% (9)
9.8% (5) 4.8% (1) 8.3% (6)
64.7% (33) 76.2% (16) 68.1% (49)
2.0% (1) 4.8% (1) 2.8% (2)
21.6% (11) 4.8% (1) 16.7% (12)
56.9% (29) 38.1% (8) 51.4% (37)
19.6% (10) 52.4% (11) 29.2% (21)
Abbreviations
and Acronyms
AR  aortic regurgitation
EOA  effective orifice
area
EuroSCORE  European
System for Cardiac
Operative Risk Evaluation
HRinop  high-risk
inoperable
HRop  high-risk operable
MACCE  major adverse
cardiovascular and
cerebrovascular event(s)
MR  moderate risk
NYHA  New York Heart
Association
TAVI  transcatheter aortic
valve implantation
TIA  transient ischemic
attack-Risk
4)
4.9
0)
8.53
9)
1)
1)
2)
9)
0)
)
)
0)
)
1)
)
9)
/19)
0)
)
)
1)
)
3)
1)
)isk Evaluation; NYHA  New York Heart Association; TIA  transient ischemic attack.
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CoreValve 2-Year Follow-Up April 19, 2011:1650–7were provided with baseline case report forms, logistic
EuroSCORE, and available source documentation for each
patient. All patients provided written informed consent
before the procedure. The study was approved by the local
ethics committees at each institution.
Device and procedure. Design characteristics of the Core-
Valve prosthesis as well as the procedural characteristics
have been described elsewhere (2,3). Briefly, the current
18-F generation of the CoreValve prosthesis consists of a
trileaflet bioprosthetic porcine pericardial tissue valve, which
is mounted and sutured in a self-expanding nitinol stent
frame. The device is implanted retrogradely. The currently
commercially-available third-generation device analyzed in
this study is offered in 2 different sizes (26- and 29-mm
prosthesis) for different annulus dimensions ranging from
20 to 27 mm. As of May 2007, only the 26-mm prosthesis
was available and implanted.
Definitions. The MACCE were defined as the composite
of all-cause death, myocardial infarction, emergent cardiac
surgery or percutaneous reintervention, and stroke. Myocar-
dial infarction was defined as elevation of creatine kinase
twice the upper limit of normal in the presence of elevated
creatine kinase-myocardial band above the upper limit of
normal, with electrocardiographic evidence of ischemia and
a compatible clinical history. Stroke was defined as a new
prolonged (24 h) or permanent neurological deficit and
radiographic imaging demonstrating an acute ischemic cere-
brovascular event. Technical success was defined as success-
ful device implantation without valve misplacement or
malfunction at the index procedure. Procedural success was
defined as successful device implantation without occur-
rence of MACCE during index hospitalization. Structural
valve deterioration was defined as any change in function of
the study valve resulting from an intrinsic abnormality of the
valve that causes stenosis or regurgitation.
Statistical analysis. Categorical variables are presented as
frequencies and percentages and were compared by chi-
square test or Fisher exact test. Continuous variables are
presented as mean  SD, and were compared by unpaired
Student t test. Survival and other time-to-event analyses at
2 years were performed by Kaplan-Meier analysis. A p value
0.05 was considered statistically significant.
Results
Baseline characteristics and procedural results. A total of
126 patients were enrolled between 2006 and 2008 at 9 sites
in Europe and Canada. Baseline patient characteristics are
listed in Table 1. The risk classification grouped the study
population into 54 patients with moderate-risk (MR
[42.9%]), 51 patients with high but operable risk (HRop
[40.5%]), and 21 patients with high inoperable risk (HRinop
[16.7%]). The mean EuroSCORE was 23%, and was almost
twice as high for high-risk patients as compared with
moderate-risk patients (28.9% vs. 16.1%, respectively).30 T A C M S T E S
E
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April 19, 2011:1650–7 CoreValve 2-Year Follow-UpWithin the high-risk group, the inoperable high-risk group
had a higher incidence of New York Heart Association
(NYHA) functional class IV (19.6% HRop vs. 52.4%
HRinop) and pulmonary hypertension (41.2% HRop vs.
61.9% HRinop). All patients in the moderate-risk group
underwent the procedure through the femoral access route
whereas 2 patients in the high-risk group underwent the
procedure through the left subclavian approach.
The overall technical and procedural success rates were
83.1% and 72.6%, respectively. High-risk patients com-
pared with moderate-risk patients had similar rates of tech-
nical success (84.7% vs. 80.8%), whereas procedural success
was lower in the high-risk group than in the moderate-risk
group (69.4% vs. 76.9%). Post-procedural implantation of
permanent pacemakers due to atrioventricular conduction
abnormalities was required for 26.2% of all patients.
Follow-up. MACCE. Follow-up availability was 99.2%
(125 of 126) at 30 days and 87.3% (110 of 126) at 2 years.
The overall MACCE rate at 30 days amounted to 26.4%,
with an all-cause mortality of 15.2% and a rate of stroke of
9.6% (Table 2). At 2 years, the overall MACCE rate
increased to 47.4%, with a significantly higher MACCE
rate in the high-risk inoperable group (69.4%) compared
with the moderate-risk group (40.3%) (Fig. 1). All-cause
mortality increased from the 30-day to 2-year follow-up
period from 15.2% to 38.1% in the overall population, with
a significant difference between the moderate- and high-
risk groups (27.8% vs. 45.8%, p  0.04) (Fig. 2). Cardiac
mortality rates at 2 years were similar among patients of the
Figure 1 Freedom From MACCE
Kaplan-Meier estimates of freedom from major adverse cardiac and cerebrovascul
blue line indicates high-risk operable (Op); red line indicates high-risk inoperable (moderate- and high-risk operable groups (18.5% vs. 17.6%)
(Fig. 3).
ECHOCARDIOGRAPHIC OUTCOME. Comparing baseline
and 30-day echocardiographic follow-up data, there was a
significant reduction of the mean transvalvular gradient
from 46.8  15.9 mm Hg to 8.5  4.0 mm Hg in the
overall population, with similar results in all subgroups
(Fig. 4). The hemodynamic status remained essentially
unchanged between the 30-day and 2-year follow-up pe-
riod, with a mean pressure gradient of 9.0  3.4 mm Hg at
2 years. Aortic regurgitation of any kind was present in 58%
of patients at baseline compared with 41% and 37% at 30
days and 2 years after the intervention, respectively. There
was no severe aortic regurgitation (3/4) at any time
(Fig. 5). There was no report of structural valve deteriora-
tion, frame fractures, or valve migrations up to 2 years, and
only 1 case of endocarditis.
FUNCTIONAL OUTCOME. Figure 6 shows the change in
linical status based on the NYHA functional classification
t various times for the overall population as well as for the
ubgroups compared with the baseline status. At 30 days,
0% of all patients with technical success improved by at
east 1 NYHA level, 15% remained unchanged, and 5%
orsened. This clinical improvement was apparent in all
ubgroups, with the greatest benefit among patients in the
igh-risk groups. At 2 years, 74% of patients still reported
unctional improvement, 16% reported the same status as
efore the intervention, and 10% had worsened.
nts (MACCE) up to 2-year follow-up (FU). Black line indicates total group;
and green line indicates moderate risk.ar eve
Inop);
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CoreValve 2-Year Follow-Up April 19, 2011:1650–7Figure 2 Freedom From All-Cause Mortality
Kaplan-Meier estimates of freedom from all-cause mortality up to 2-year FU. Black line indicates total group;
blue line indicates high-risk Op; red line indicates high-risk Inop; and green line indicates moderate risk. Abbreviations as in Figure 1.Figure 3 Freedom From Cardiac Mortality
Kaplan-Meier estimates of freedom from cardiac mortality up to 2-year FU. Black line indicates total group;
blue line indicates high-risk Op; red line indicates high-risk Inop; and green line indicates moderate risk. Abbreviations as in Figure 1.
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April 19, 2011:1650–7 CoreValve 2-Year Follow-UpDiscussion
This study provides evidence of the durability of both the
safety and the efficacy of TAVI using the self-expanding
Medtronic CoreValve prosthesis for the treatment of pa-
Figure 4 Mean Gradient and EOA Area
Mean pressure gradient (Pmean) and effective orifice area (EOA) assessed by ech
ble (HRop); solid red line is Pmean high-risk inoperable (HRinop); solid green line
indicates EOA HRop; dashed red line indicates EOA HRinop; dashed green line ind
Figure 5 Aortic Valve Regurgitation
Pre-procedural and post-procedural aortic valve regurgitation assessed by echocartients with severe aortic valve stenosis. Two years after
implantation and independent of pre-procedural risk fea-
tures, there was no evidence of structural valve deterioration
or significant changes of the hemodynamic status of the
graphy. Solid black line is Pmean total; solid blue line is Pmean high-risk opera-
an moderate risk (MR). Dashed black line indicates EOA total; dashed blue line
EOA MR. FU  follow-up.
hy. AR  aortic regurgitation; FU  follow-up.ocardio
is Pme
icatesdiograp
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CoreValve 2-Year Follow-Up April 19, 2011:1650–7prostheses. There was only 1 case of prosthetic valve
endocarditis at 2 years of follow-up (0.8%  0.4% annual
risk), which is well within the range of surgical series of
bioprosthetic aortic valve replacement, with a reported
annual risk of approximately 0.6% (8). Accordingly, tech-
nical performance of the device appears to be durable so far.
The procedural success rate of only 73% compared with
reported rates of 90% to 97% in more recent studies
(2,5–7,9) is related to learning phase factors as well as a very
conservative definition used in this study requiring
MACCE-free in-hospital survival, without which the tech-
nical success rate was 83%. Similarly, the 30-day mortality
rate of 15.2% in this study appears to be high in the light of
more recent TAVI studies, which report 30-day mortality
rates of 6% to 10% (5–7,9). In addition to the learning curve
issues and various improvements described, that might be
related to a tendency to treat patients with less comorbidity
today than in the early phase of TAVI, as is reflected in this
paper.
Between 30-day and 2-year follow-up, we observed a 2-
to 3-fold increase in all-cause mortality, which is in line
with a previous publication by Gurvitch et al. (10) of
patients undergoing TAVI using a balloon-expandable
prosthesis. In this publication, a follow-up of 3 years is
Figure 6 Functional Clinical Outcome
Functional status expressed by New York Heart Association (NYHA) classification a
Dark green  improved 3 levels; medium green  improved 2 levels; light green
dark yellow  worsened 2 levels. HR  high risk; inop  inoperable; MR  modereported, with a 2-year survival of 74% of patients whosurvived the first 30 days after the procedure, and an overall
2-year survival of 64%. Our data demonstrate that this
mortality is strongly influenced by pre-procedural risk char-
acteristics. Patients classified high-risk before the interven-
tion had twice the risk of major adverse events up to 2 years
compared with patients in the moderate-risk group, under-
lining the importance of pre-existing comorbidities. Al-
though there was no difference in cardiac deaths between
the moderate-risk and the high-risk operable groups, there
was a significant difference in all-cause mortality due to
more noncardiac events in the high-risk population, indi-
cating that high-risk patients do not have a higher likeli-
hood of dying for procedural or valve-related reasons but for
reasons originating from their pre-existing comorbidities.
Clinical improvement among survivors was remarkable and
durable, particularly in high-risk subgroups.
The occurrence of strokes during a TAVI procedure is
reported with an incidence of 2% to 4% in more recent
publications (5–7,9), which appears acceptable in light of
the high-risk patient population and compares favorably
with surgical studies of aortic valve replacement. The
reported 30-day stroke rate of 9.6% in our study is the
result of the definition of stroke accounting for any
defects on imaging studies (3 patients did not have any
harge, and at 30-day and 2-year follow-up (FU) compared with baseline.
roved 1 level; light yellow  no change; medium yellow  worsened 1 level;
sk; op  operable; T  total.t disc
 imp
rate riclinical deficits by neurological examination, but had
t
I
H
H
s
a
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April 19, 2011:1650–7 CoreValve 2-Year Follow-Upsmall defects on imaging studies). Therefore, it is difficult
to compare this rate with other reports using different
definitions. Future studies will certainly benefit from the
consensus on standardized outcome definitions that are
currently prepared by the Valve Academic Research
Consortium representing several academic research orga-
nizations, surgical and cardiological professional societ-
ies, members of the U.S. Food and Drug Administration,
and independent experts. However, embolic cerebral
events remain an important issue that is stimulating the
development of various protection concepts entering
clinical investigation.
Study limitations. This is a multicenter, prospective study
with independent monitoring and event adjudication, but
the lack of randomization limits the ability to compare these
data with established treatment standards. In addition,
small subgroup sizes might affect interpretation of the data.
When comparing the mortality result with the calculated
EuroSCORE, which was standard at the time of patient
enrollment and, therefore, the only score used in this study,
one has to consider that today this score is known to be of
limited value to characterize the risk for patients undergoing
valve replacement and captures only a limited number of
risk-predicting characteristics (e.g., porcelain aorta is not
considered) (11). Therefore, new scores and algorithms for
the combined field of transcatheter and surgical aortic valve
replacement should be developed to accurately describe the
pre-procedural patient risk to be able to select the best
treatment option for the specific patient. Finally, follow-up
of this study will continue up to 4 years, and additional
long-term studies are needed before durability of these new
devices can be confirmed according to surgical standards.
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